SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals (VNDA) is trending sharply following FDA approval of BYSANTI for bipolar I disorder and schizophrenia, fueling community excitement for substantial upside, a potential short squeeze, and speculation that the approval strengthens the case for future pipeline successes and a possible acquisition.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

Crowdstrike is trending amidst a sector-wide sell-off driven by concerns that Anthropic's new Claude Code Security AI tool could disrupt cybersecurity, though the community remains divided, with many asserting minimal overlap with CRWD's core offerings while others caution about its high valuation.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending due to community bewilderment surrounding its bearish reaction to the Supreme Court's decision to strike down tariffs, a development widely anticipated as a significant positive given the company's prior reported tariff costs, fueling discussions of market manipulation.

JFrog Ltd. engages in the provision of an end-to-end, hybrid, universal development operations platform that powers and controls the software supply chain, which enables organizations to continuously and securely deliver software updates across any system. It operates through the following geographical segments: United States, Israel, India, and Rest of World. The firm is also involved in creating software delivered without friction from developer to device. The company was founded by Frederic Simon, Shlomi Ben Haim, and Yoav Landman in 2008 and is headquartered in Sunnyvale, CA.

JFrog Ltd

JFrog is trending due to a significant sell-off following Anthropic's Claude Code Security preview, prompting community debate over whether new AI tools will disrupt traditional DevSecOps solutions. While some view the market's reaction as overdone and a buying opportunity, others express concern about AI's potential impact on software supply chain security.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR Protocol is gaining significant traction for its deep integration into the AI sector, including a partnership with NVIDIA, and its robust advancements in cross-chain interoperability with projects like Starknet. The community is actively discussing its "invisible engine" technology, rapid user growth, and strong potential in the anticipated altcoin season.

Figure Technology Solutions, Inc. is a blockchain-native capital marketplace, which engages in connecting origination, funding, and secondary market activity. It operates through the following segments: FTI, Markets, and Other. The FTI segment offers Figure Connect which generates ecosystem and technology fees, and originates, sells, and securitizes home equity line of credit (HELOC) loans that it services. The Markets segment utilizes blockchain technology to develop an exchange for digital assets and credit, with new product offerings including providing interest-bearing stable coin deposits. The company was founded by Michael Scott Cagney and June Ou in 2018 and is headquartered in Reno, NV.

Figure Technology Solutions Inc. - Ordinary Shares - Class A

Figure Technology Solutions Inc

Figure Technology Solutions is experiencing extreme volatility and a sharp price decline, igniting a fierce debate among investors. While many bulls view this as a generational buying opportunity for a fundamentally strong leader in blockchain-based lending and real-world asset tokenization, citing strong earnings guidance, a significant portion of the community dismisses it as a "pump and dump" scam, questioning its valuation amidst a broader unraveling of the blockchain RWA narrative ahead of its upcoming earnings report.

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

Blue Owl Capital is trending due to a change in its retail credit fund's redemption policy, which, despite management's claims of accelerating capital return, has ignited community fears of liquidity issues spreading across the private credit market and raised questions about its large data center financing deals.

Las Vegas Sands Corp. engages in the development of destination properties. It operates through the Macao and Singapore geographical segments. The Macao segment handles the operations of The Venetian Macao, The Londoner Macao, The Parisian Macao, The Plaza Macao and Four Seasons Macao, and Sands Macao. The Singapore segment includes the Marina Bay Sands. The company was founded by Sheldon Gary Adelson in August 2004 and is headquartered in Las Vegas, NV.

Las Vegas Sands Corp

Las Vegas Sands is trending as its latest earnings, marked by record Singapore strength against weaker Macau performance, led to a notable stock decline, sparking community debate over the market reaction and continued speculative call option activity.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is trending following its Q4 earnings beat, which showcased narrower losses, improved operational metrics, and the launch of a new mortgage product in beta, signaling a path towards adjusted profitability. The community is actively debating whether these strategic shifts mark a true turnaround for the iBuying model, especially with broader market optimism around potential future rate cuts that could benefit the real estate sector, while others remain skeptical of sustained momentum and point to market manipulation.

Bombardier Cl B Sv

Bombardier is a key topic following strong financial reports, including exceeding guidance and securing new orders, as the community actively debates its market valuation and navigates the political noise around potential tariffs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Jupiter Asset Management Ltd. Purchases 129,971 Shares of Halozyme Therapeutics, Inc. $HALO

Jupiter Asset Management Ltd. boosted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 19.4% in the 3rd quarter, according to its most recent filing with the...

Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $90.00

Benchmark increased their price target on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a "buy" rating in a research report on Thursday...

Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $75.00 at Wells Fargo & Company

Wells Fargo & Company increased their price target on Halozyme Therapeutics from $65.00 to $75.00 and gave the company an "equal weight" rating in a research report on Thursday...

Halozyme Therapeutics (NASDAQ:HALO) Stock Price Down 8.7% Following Weak Earnings

Halozyme Therapeutics (NASDAQ:HALO) Stock Price Down 8.7% on Disappointing Earnings...

Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues

HALO swings to Q4 loss on acquisition charge, but revenues surge 52%, fueled by royalties and product sales and top estimates.

Halozyme Therapeutics, Inc. $HALO Shares Sold by Hodges Capital Management Inc.

Hodges Capital Management Inc. trimmed its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 21.0% during the third quarter, according to its most recent filing with the...

Halozyme Therapeutics (NASDAQ:HALO) Announces Quarterly Earnings Results, Misses Expectations By $2.16 EPS

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing...

Halozyme Therapeutics Q4 Earnings Call Highlights

Halozyme Therapeutics (NASDAQ:HALO) executives highlighted what they described as a significant and value-creating 2025, pointing to accelerating royalty growth from ENHANZE-enabled products...

Here's What Key Metrics Tell Us About Halozyme Therapeutics (HALO) Q4 Earnings

The headline numbers for Halozyme Therapeutics (HALO) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -111.16% and +0.70%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Current Price	$70.98
Prev Close	$72.04
Open	$71.71
Dividend Yield	0.00%
50-Day Moving Average	$71.23
Beta	0.72
Avg. Volume	1.88M
PE Ratio	28.91

52-Week High	$82.22
52-Week Low	$47.50
Market Capitalization	$8.5B
EPS (Annual)	$2.56
Price to Book	173.82
Revenue Per Employee	$3.3M

HALO
Halozyme Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HALO News

HALOHalozyme Therapeutics Inc.